sameAs
Triple in Asthma Dose FindingConfirmatory Dose Finding Study of 2 Dosages of CHF 4226 pMDI (Carmoterol) in Patients With COPDEfficacy and Safety of Nebulised Beclomethasone Dipropionate Plus as Needed Salbutamol vs as Needed Salbutamol or as Needed Salbutamol/Beclomethasone Fixed Combination in Young Children With Asthma SymptomsClinical Trial of the Efficacy and Safety of Beclomethasone Dipropionate Plus Formoterol vs Fluticasone Propionate Plus Salmeterol in the 6 Months Step Down Treatment of AsthmaObservational Study on the Prophylactic Use of Curosurf in Neonatal Respiratory Distress Syndrome (RDS)Cross-over Study to Evaluate the Effect on Trough Forced Expiratory Volume in One Second (FEV1) After 4 Weeks Treatment With CHF 5188 pMDI qd in Adult Patients With Persistent AsthmaClinical Pharmacology of CHF 1535 50/6 ug Next DPI in Children 5-11 Years OldComparison of Combination of Beclomethasone Dipropionate and Formoterol Fumarate Versus Single Components Assessed by Knemometry and Urinary Cortisol Measurements in Asthmatic ChildrenA Phase II, 5-way Cross-over Study to Evaluate the Pharmacodynamics of "Nexthaler" Dry Powder Inhaler in COPD PatientsEfficacy of Combining Prophylactic Curosurf With Early Nasal CPAP in Delivery Room: the Curpap StudyNext DPI LABA, Multicentre, 5-way Cross-over, Adult Asthmatic PatientsA Study Comparing the Efficacy and Safety of CHF 1535 (BDP +FF) Inhalation Powder, Administered Via the NEXT Inhaler, Versus CHF 1535 (BDP +FF), Administered Via a pMDI, in Moderate to Severe AsthmaEfficacy and Tolerability of Beclomethasone Dipropionate/Formoterol Single Inhaler in Patients With Mild to Moderate Persistent AsthmaStudy Comparing Foster Efficacy Maintenance and Reliever Versus Foster Maintenance + Salbutamol Reliever in AsthmaticsA Study To InvestigateThe Safety, Tolerability And Efficacy Of Nebulised Curosurf® In Preterm Neonates With Respiratory Distress Syndrome (RDS)Formoterol Via pMDI HFA-134a Propellant or DPI in Partially Reversible Chronic Obstructive Pulmonary Disease (COPD)Efficacy and Safety of CHF 1535 200/6µg in Not Adequately Controlled Asthmatic PatientsPrevalence and Reversibility of Lung Hyperinflation in AsthmaA Study in Patients With AsthmaRandomized Cross Over Study to Assess Efficacy and Safety of BDP/FF and GlycopyrrolateEfficacy Study of the Product "CHF 1535" Versus Beclomethasone (BDP) and Free Combo in Asthmatic ChildrenA Study in Patients With Chronic Obstructive Pulmonary Disease (FAIR)Pharmacokinetic Clinical Study of CHF1535 NEXT DPI® Versus CHF1535 pMDIEfficacy Of Clodronate 200 Mg/4 Ml I.M. Solution With 1% Lidocaine Every Other Week Vs Clodronate 100 Mg/3,3ml I.M. Solution With 1% Lidocaine Once-Week In A 1-Year Treatment Period Of Women With Postmenopausal OsteoporosisEfficacy of CHF1535 Via NEXT DPI Versus pMDI and BDP DPI100µg on PeakExpiratoryFlow in Asthmatic PatientsStudy to Investigate the Effect of Formoterol vs Salmeterol on Small Airways Physiological Parameters in COPD PatientsFoster 100/6 mg NEXThaler Versus Foster 100/6mg Pressurized Metered-dose Inhaler (pMDI) in Patients With Controlled Asthma.A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Doses of CHF6297 in Healthy Subjects and Patients With COPDFoster® pMDI (CHF 1535) Versus Symbicort® Turbohaler in COPD PatientLung Deposition of TRIMBOW® pMDI in Healthy Volunteers, Asthmatic and COPD PatientsEfficacy of Fixed Combination of Beclomethasone Dipropionate (BDP) + Formoterol Fumarate (FF) + Glycopyrronium Bromide (GB) (CHF 5993)Administered Via Dry Powder Inhaler (DPI) in Chronic Obstructive Pulmonary Disease (COPD)
P859
Q61894598-3EDABDF1-ACA3-4CC6-AA59-3AB8AFA850B9Q61914922-1F9B1B0B-F39E-416A-85CC-4E20A1F204F3Q61917402-AFACCC5C-4528-4C2F-9A4F-337F5847373CQ61917426-9A8AB1FD-6BBE-4954-A522-0497FE4EA810Q61935891-D2050C0E-B74E-4527-AB0A-1523786E2DFFQ61938796-8538460C-B65F-48BE-AF8C-870AEC4B74A7Q61956015-5C966184-DF8C-45A1-B3F4-E86A23B6C3B3Q61967367-C129080A-7A66-424D-A7D8-4E5EE1717634Q61969277-387ACDD1-1354-4269-90F2-2E4EA30ABB69Q61980288-F32FA5E6-DF34-4BF2-AC4A-4BBD45C75A14Q61980845-4BF2C04E-B9C7-4136-843E-10EFAABBA3F1Q61981324-FAC1057A-575A-475B-A1CA-4C1A0A02292EQ61981335-A882C210-6303-4D68-B527-A33B193F8337Q61981359-0F6DBA13-592B-4B1A-9753-26F39785D415Q63011343-C49F921A-9650-403E-9A08-2EECE730D87CQ63062605-7733C568-F3B7-44E9-9891-09D4061AD7DCQ63315637-B4D6D197-76A7-470A-8D7D-3D3608198508Q63316127-96C4ED41-75D2-4DF8-9E68-56D37688592DQ63316878-C65167C4-186C-4FA8-86CC-5D2A39B7C8EBQ63320701-5F083CA2-BAF8-4DAB-A758-2AC7E1083F55Q63321145-6D38DEEF-BC0C-4094-A3C7-62A119480DF3Q63334406-774867B4-8713-425D-8E87-95D0AC449A63Q63335265-B2825ECD-F61E-4A3E-9257-226F2FA9CD00Q63335535-8722C8B9-6978-4CF3-BFE2-65345AFADEE0Q63336236-13F16378-7085-400E-BE9E-1B889B30DA2CQ63336666-78F18A2C-3348-4AD0-AFE5-776D357E23AAQ63400640-51D8E985-DDBF-498A-A29B-E4C992FACFBFQ63577746-943A2DE0-41B3-433C-9A2F-079D3C36630AQ63581211-4E542307-9258-4ED1-9600-46FEEFDC1AAAQ63593117-9651FCA6-3E8C-49AD-BA37-452CCC7244E2Q63599729-40A0C971-0062-47EB-B042-161B4BC67EF8
P859
description
Compañía farmacéutica multinac ...... quelético y para neonatología.
@es
bedrijf uit Italië
@nl
name
Chiesi Farmaceutici S.p.A.
@en
Chiesi Farmaceutici S.p.A.
@fr
Chiesi Farmaceutici S.p.A.
@nl
Chiesi Farmaceutici
@it
Chiesi
@da
Chiesi
@sv
Grupo Chiesi Farmacéutico
@es
Grupo Farmacéutico Chiesi
@gl
type
label
Chiesi Farmaceutici S.p.A.
@en
Chiesi Farmaceutici S.p.A.
@fr
Chiesi Farmaceutici S.p.A.
@nl
Chiesi Farmaceutici
@it
Chiesi
@da
Chiesi
@sv
Grupo Chiesi Farmacéutico
@es
Grupo Farmacéutico Chiesi
@gl
altLabel
Grupo Chiesi Farmaceutico
@es
Grupo Chiesi
@es
Grupo Farmaceutico Chiesi
@es
Grupo Farmacéutico Chiesi
@es
prefLabel
Chiesi Farmaceutici S.p.A.
@en
Chiesi Farmaceutici S.p.A.
@fr
Chiesi Farmaceutici S.p.A.
@nl
Chiesi Farmaceutici
@it
Chiesi
@da
Chiesi
@sv
Grupo Chiesi Farmacéutico
@es
Grupo Farmacéutico Chiesi
@gl
P3153
P6366
P1454
P159
P17
P213
0000 0004 1761 6733
P2427
grid.467287.8
P2657
974918817911-97
P3153
P571
1935-01-01T00:00:00Z